Dozens of testosterone treatment lawsuits have been filed in federal court on behalf of men who allegedly suffered heart attacks, strokes, and venous blood clots such deep vein thrombosis and pulmonary embolism, due to testosterone therapy.
New York, NY (PRWEB) June 23, 2014
As testosterone lawsuit (http://www.testosteronelawsuitclaims.com/) filings continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the Food & Drug Administration (FDA) is warning of a potential risk for venous blood clots among men who use low testosterone therapy medications. According to an FDA alert dated June 20, 2014, the agency is requiring the manufacturers of all approved testosterone products to include a warning in the drug labeling about the potential for venous blood clots, including deep vein thrombosis and pulmonary embolism.*
The alert also noted that the labeling for testosterone products already includes information about venous blood clots that may occur due to the development of polycythemia, a condition marked by an abnormal increase in red blood cells. However, this latest FDA action was prompted by post-market reports of venous blood clots in patients undergoing testosterone replacement that were unrelated to the development of polycythemia.
“Dozens of testosterone treatment lawsuits have been filed in federal court on behalf of men who allegedly suffered heart attacks, strokes, and venous blood clots such deep vein thrombosis and pulmonary embolism, due to testosterone therapy. The FDA alert only serves to remind that these medications may be associated with very serious side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm offers free testosterone treatment lawsuit reviews to men who were allegedly harmed by medications included in this class.
Prescription testosterone therapies are approved to treat low testosterone in men who suffer from the condition due to an underlying medical issue. Medications in this class include:* *
- Bio-T Gel
According to the FDA’s June 20th alert, the new blood clot warning is not related to the agency’s ongoing review of heart risks potentially associated with low testosterone therapy. That review, which was announced by the FDA on January 31, 2014, was prompted by the publication of two studies that suggest older men and those with pre-existing heart problems might face a higher risk of heart attacks, strokes and sudden death.
Since the FDA issued that alert, court records indicate nearly 100 testosterone treatment lawsuits have been filed in U.S. courts on behalf of men who allegedly suffered life-threatening cardiovascular problems, including heart attacks, strokes, heart failure, deep vein thrombosis, and pulmonary embolism, due to their use of low testosterone therapy. All federally-filed testosterone lawsuits have been consolidated in a multidistrict litigation that is now underway in U.S. District Court, Northern District of Illinois. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Men who allegedly suffered serious heart problems due to their use of testosterone replacement drugs may be entitled to file their own testosterone lawsuit. To learn more about the risks potentially associated with low testosterone therapy, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm, FDA, June 20, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com